BRAF-inhibition and tumor immune suppression

摘要

As BRAF(V600E)-inhibitors become standard treatment for many metastatic melanoma patients, research has begun to elucidate their impact on the tumor immune landscape. Here, we highlight our recent studies demonstrating the ability of melanoma cell-intrinsic BRAF(V600E)-inhibition to selectively reduce intratumoral immunosuppressive cell populations and enhance antitumor CD8(+) T-cell immunity.